Clinical Trial Update: Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update comparing two lots of NBP608 to Zostavax, assessing immunogenicity and safety in healthy adults aged 50 and over for herpes zoster.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• NBP608
• Zostavax (Varicella zoster vaccine live)

Snippet

Sponsor: SK Chemicals Co., Ltd. | Conditions: Herpes Zoster | Phase 2, Phase 3 | Status: COMPLETED